title: Inhibition of mechanical stress-induced hypertrophic scar inflammation by emodin.
abstract: At least 50% of hypertrophic scarring (HS) is characterized by inflammation, for which there is currently no effective treatment available. Emodin is a major component of the widely used Chinese herb, rhubarb, which has been used to treat inflammation in several types of disease. However, few studies have investigated the efficacy of emodin in the treatment of HS. In the present study, a mouse model with mechanical stress‑induced HS was used to investigate the effects of emodin (20, 40, 80, or 120 mg/ml) on HS, and to determine the potential underlying mechanisms. Treatment with emodin significantly attenuated HS inflammation, as determined by histopathological assessment of the scar elevation index, collagen structure and inflammation (P<0.05). Furthermore, treatment with emodin (40 mg/ml) markedly inhibited phosphoinositide 3‑kinase (PI3K)/Akt activity (P<0.01) and this attenuation was associated with reduced expression levels of tumor necrosis factor‑α, interleukin‑6 and monocyte chemoattractant protein‑1 (P<0.05) in the HS tissue. The results of the present study indicated that administration of emodin had therapeutic effects on the progression of HS and the underlying mechanism of this may be due to inhibition of the PI3K/Akt signaling pathway.
authors: Department of Plastic Surgery, Jiangxi Provinicial People's Hospital, Nanchang, Jiangxi 330006, P.R. China.
authors: Cheng
authors: C
authors: Liu
mesh_terms: D000818:Animals; D017439:Cicatrix, Hypertrophic / Q000150:complications* / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D004642:Emodin / Q000627:therapeutic use*; D005260:Female; D007249:Inflammation / Q000150:complications* / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D008810:Mice, Inbred C57BL; D019869:Phosphatidylinositol 3-Kinases / Q000276:immunology; D051057:Proto-Oncogene Proteins c-akt / Q000276:immunology; D015398:Signal Transduction / Q000187:drug effects; D013314:Stress, Mechanical
chemical_list: D004365:Drugs, Chinese Herbal; D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt; D004642:Emodin
references: J Pathol. 2004 Apr;202(4):476-85
references: 15095275
references: Int Wound J. 2014 Oct;11(5):517-22
references: 23173565
references: J Invest Dermatol. 1998 Nov;111(5):828-34
references: 9804346
references: J Invest Dermatol. 2007 Mar;127(3):514-25
references: 17299434
references: Wound Repair Regen. 2003 Sep-Oct;11(5):331-6
references: 12950636
references: FASEB J. 2007 Oct;21(12):3250-61
references: 17504973
references: Invest Ophthalmol Vis Sci. 2007 Nov;48(11):5013-22
references: 17962452
references: J Pathol. 2008 Jan;214(2):199-210
references: 18161745
references: Int Immunopharmacol. 2008 May;8(5):741-7
references: 18387517
references: Planta Med. 2008 Aug;74(10):1246-52
references: 18612943
references: Parasite Immunol. 2008 Sep;30(9):487-90
references: 18627508
references: Burns. 2009 Feb;35(1):15-29
references: 18952381
references: Dermatol Surg. 2009 Feb;35(2):171-81
references: 19215252
references: Nephrol Dial Transplant. 2009 Oct;24(10):3033-41
references: 19474275
references: Hepatology. 2009 Nov;50(5):1512-23
references: 19790269
references: Am J Pathol. 2010 Feb;176(2):679-86
references: 20042669
references: Wound Repair Regen. 2010 Jul-Aug;18(4):401-8
references: 20546553
references: Ann Plast Surg. 2010 Sep;65(3):321-5
references: 20733369
references: Mol Med. 2011 Jan-Feb;17(1-2):113-25
references: 20927486
references: Biol Pharm Bull. 2011;34(9):1432-7
references: 21881229
references: Int J Oncol. 2011 Dec;39(6):1381-90
references: 21805032
references: FASEB J. 2011 Dec;25(12):4498-510
references: 21911593
references: Nat Med. 2012 Jan;18(1):148-52
references: 22157678
references: Burns. 2012 Aug;38(5):668-76
references: 22226222
references: Burns. 2012 Aug;38(5):677-84
references: 22360962
references: J Invest Dermatol. 2013 May;133(5):1351-60
references: 23303451
references: Oncol Rep. 2013 Dec;30(6):2555-62
references: 24065213
references: Cancer Lett. 2013 Dec 1;341(2):139-49
references: 23962559
references: Sci Rep. 2013;3:3470
references: 24326778
references: Int J Mol Med. 2014 Feb;33(2):478-86
references: 24276150
references: J Korean Med Sci. 2014 Feb;29(2):230-7
references: 24550650
references: J Burn Care Rehabil. 1997 Nov-Dec;18(6):477-82
references: 9404979